Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure

Medicine & Life Sciences

• Risk Reduction Behavior 100%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 95%
• Chronic Renal Insufficiency 89%
• Chronic Kidney Failure 86%
• Renal Dialysis 24%
• Myocardial Infarction 20%
• Homocysteine 15%
• Proxy 14%
• Primary Prevention 14%
• Secondary Prevention 13%
• Minerals 13%
• Dialysis 11%
• Coronary Artery Disease 11%
• Population 10%
• Oxidative Stress 10%
• Placebos 9%
• Randomized Controlled Trials 9%
• Prospective Studies 8%
• Morbidity 8%
• Kidney 7%
• Serum 6%